Additionally, copanlisib (a pan class I PI3K inhibitor), duvelisib (a p110γ/p110δ inhibitor), and idelalisib (a p110δ inhibitor) are approved to treat adult patients with relapsed or refractory follicular lymphoma, but not solid tumors, with RAS mutations. Here, PIK3CD is linked to follicular lymphoma.